Page 603 - Read Online

Ralph et al. J Cancer Metastasis Treat 2018;4:49 I http://dx.doi.org/10.20517/2394-4722.2018.42 Page 23 of 26

signaling pathway. J Recept Signal Transduct Res 2014;34:396-400.
71. Ji L, Liu R, Zhang XD, Chen HL, Bai H, Wang X, Zhao HL, Liang X, Hai CX. N-acetylcysteine attenuates phosgene-induced acute lung
injury via up-regulation of Nrf2 expression. Inhal Toxicol 2010;22:535-42.
72. Wang LL, Huang YH, Yan CY, Wei XD, Hou JQ, Pu JX, Lv JX. N-acetylcysteine ameliorates prostatitis via miR-141 regulating Keap1/
Nrf2 signaling. Inflammation 2016;39:938-47.
73. Moss RW. Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants? Integr Cancer Ther 2006;5:63-82.
74. Chio IIC, Tuveson DA. ROS in cancer: the burning question. Trends Mol Med 2017;23:411-29.
75. Hiramoto K, Satoh H, Suzuki T, Moriguchi T, Pi J, Shimosegawa T, Yamamoto M. Myeloid lineage-specific deletion of antioxidant system
enhances tumor metastasis. Cancer Prev Res (Phila) 2014;7:835-44.
76. Le Gal K, Ibrahim MX, Wiel C, Sayin VI, Akula MK, Karlsson C, Dalin MG, Akyürek LM, Lindahl P, Nilsson J, Bergo MO. Antioxidants
can increase melanoma metastasis in mice. Sci Transl Med 2015;7:308re8.
77. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85-95.
78. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO. Antioxidants accelerate lung cancer progression in mice. Sci Transl
Med 2014;6:221ra15.
79. Zhang Z, Yan J, Taheri S, Liu KJ, Shi H. Hypoxia-inducible factor 1 contributes to N-acetylcysteine’s protection in stroke. Free Radic Biol
Med 2014;68:8-21.
80. Haddad JJ, Olver RE, Land SC. Antioxidant/pro-oxidant equilibrium regulates HIF-1alpha and NF-kappa B redox sensitivity. Evidence for
inhibition by glutathione oxidation in alveolar epithelial cells. J Biol Chem 2000;275:21130-9.
81. Jin WS, Kong ZL, Shen ZF, Jin YZ, Zhang WK, Chen GF. Regulation of hypoxia inducible factor-1α expression by the alteration of redox
status in HepG2 cells. J Exp Clin Cancer Res 2011;30:61.
82. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl
radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989;6:593-7.
83. Samuni Y, Goldstein S, Dean OM, Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta
2013;1830:4117-29.
84. Ezeriņa D, Takano Y, Hanaoka K, Urano Y, Dick TP. N-Acetyl cysteine functions as a fast-acting antioxidant by triggering intracellular H2S
and sulfane sulfur production. Cell Chem Biol 2018;25:447-59.
85. Kim KY, Rhim T, Choi I, Kim SS. N-acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity. J Biol
Chem 2001;276:40591-8.
86. Hayes JD, Dinkova-Kostova AT. Epigenetic control of NRF2-directed cellular antioxidant status in dictating life-death decisions. Mol Cell
2017;68:5-7.
87. Pehar M, Ball LE, Sharma DR, Harlan BA, Comte-Walters S, Neely BA, Vargas MR. Changes in protein expression and lysine acetylation
induced by decreased glutathione levels in astrocytes. Mol Cell Proteomics 2016;15:493-505.
88. Sceneay J, Liu MC, Chen A, Wong CS, Bowtell DD, Möller A. The antioxidant N-acetylcysteine prevents HIF-1 stabilization under hypoxia
in vitro but does not affect tumorigenesis in multiple breast cancer models in vivo. PLoS One 2013;8:e66388.
89. Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J, Lee LA, Semenza GL, Dang CV.
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 2007;12:230-8.
90. Zhao T, Zhu Y, Morinibu A, Kobayashi M, Shinomiya K, Itasaka S, Yoshimura M, Guo G, Hiraoka M, Harada H. HIF-1-mediated metabolic
reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs. Sci Rep 2014;4:3793.
91. Albini A, D’Agostini F, Giunciuglio D, Paglieri I, Balansky R, De Flora S. Inhibition of invasion, gelatinase activity, tumor take and
metastasis of malignant cells by N-acetylcysteine. Int J Cancer 1995;61:121-9.
92. Li L, Ren F, Qi C, Xu L, Fang Y, Liang M, Feng J, Chen B, Ning W, Cao J. Intermittent hypoxia promotes melanoma lung metastasis via
oxidative stress and inflammation responses in a mouse model of obstructive sleep apnea. Respir Res 2018;19:28.
93. Chen A, Sceneay J, Gödde N, Kinwel T, Ham S, Thompson EW, Humbert PO, Möller A. Intermittent hypoxia induces a metastatic
phenotype in breast cancer. Oncogene 2018;37:4214-25.
94. Zhu H, Jia Z, Trush MA, Li YR. Nrf2 deficiency promotes melanoma growth and lung metastasis. React Oxyg Species (Apex) 2016;2:308-
14.
95. Süleyman H, Demircan B, Karagöz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 2007;59:247-58.
96. Patrignani P, Patrono C. Cyclooxygenase inhibitors: from pharmacology to clinical read-outs. Biochim Biophys Acta 2015;1851:422-32.
97. Tsioulias GJ, Go MF, Rigas B. NSAIDs and colorectal cancer control: promise and challenges. Curr Pharmacol Rep 2015;1:295-301.
98. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B,
Godio L, Patterson S, Rodriguez-Bigas MA, Jester SL, King KL, Schumacher M, Abbruzzese J, DuBois RN, Hittelman WN, Zimmerman
S, Sherman JW, Kelloff G. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med
2000;342:1946-52.
99.Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P,
Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B; PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous
polyps. N Engl J Med 2006;355:885-95.
100. Arber N, Spicak J, Rácz I, Zavoral M, Breazna A, Gerletti P, Lechuga MJ, Collins N, Rosenstein RB, Eagle CJ, Levin B. Five-year analysis
of the prevention of colorectal sporadic adenomatous polyps trial. Am J Gastroenterol 2011;106:1135-46.
101. Burke CA, Dekker E, Samadder NJ, Stoffel E, Cohen A. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus
each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III
trial. BMC Gastroenterol 2016;16:87.
102. Lynch PM, Burke CA, Phillips R, Morris JS, Slack R, Wang X, Liu J, Patterson S, Sinicrope FA, Rodriguez-Bigas MA, Half E, Bulow
S, Latchford A, Clark S, Ross WA, Malone B, Hasson H, Richmond E, Hawk E. An international randomised trial of celecoxib versus